Post-earnings recap
Reported
Thu, Apr 30, 2026
EPS actual
$2.86
EPS est.
$2.79
EPS surprise
+2.58%
1-day move
+0.89%
ResMed's earnings report showed a positive surprise in EPS, which likely contributed to the stock's 0.89% increase. However, the lack of revenue data and management commentary leaves some uncertainty about the company's overall performance and future outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.86 | $2.81 | +2.58% |
| Revenue | N/A | $1.4B | N/A |
No transcript is on record for this earnings call, and the analysis is based solely on numerical results.
ResMed Inc. (RMD) is a leading company in the health care equipment sector, focusing on innovative solutions for sleep apnea and chronic obstructive pulmonary disease (COPD). With a market cap of $31 billion, ResMed is positioned to benefit from increasing global demand for respiratory care and sleep health solutions.
Last quarter
In Q2-2026, ResMed reported an EPS of $2.81, exceeding analyst expectations by 4.58%. However, there was no revenue figure reported, which leaves some uncertainty about overall performance.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+3.62%
Avg 1-day reaction
+0.09%
Analysts expect ResMed to report strong earnings, with a consensus EPS of $2.81. The company has a solid track record of beating earnings estimates, which could lead to positive market reactions.
Bull case
If ResMed exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its products, leading to a significant stock price increase.
Bear case
Conversely, if the company fails to meet EPS expectations or provides weak guidance, it could raise concerns about its growth prospects, resulting in a negative market reaction.
Key metrics to watch
EPS
$2.81Earnings per share is a critical measure of profitability and will indicate how well the company is managing costs and generating profits.
Revenue
$1.4BTotal revenue reflects the company's ability to grow its sales, which is essential for long-term sustainability and investor confidence.
The print will turn on these.
Q1
Will ResMed's EPS exceed the consensus estimate of $2.81?
A beat on EPS could reinforce investor confidence in the company's growth trajectory and operational efficiency.
Q2
What guidance will management provide regarding revenue growth?
Clear guidance on revenue growth is crucial for understanding the company's future performance and market position.
—
Est. EPS
$1.94
Est. Rev
$3.0B
Impl. Move
±9.9%
Why consensus could be wrong
The consensus may underestimate ResMed's ability to capitalize on the growing demand for sleep and respiratory care solutions, especially in emerging markets.
Supporting evidence
ResMed has consistently beaten EPS estimates, indicating strong operational performance.
The options market is pricing a larger move than historical averages, suggesting heightened expectations.
Recent trends in health care spending could favor companies like ResMed that provide essential medical equipment.
Key risk
If ResMed's revenue growth exceeds $1.5 billion, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is debating whether ResMed can sustain its growth amid increasing competition and changing healthcare dynamics.
Bull confirmed if
An EPS of $2.85 or higher, coupled with revenue exceeding $1.5 billion, would confirm the bull case.
Bear confirmed if
An EPS below $2.72 or revenue falling short of $1.4 billion would confirm the bear case.
What the market is pricing for the move.
Implied Move
±9.64%
Historical Avg
±0.8%
The options market is pricing in a significant move around the earnings report, suggesting that investors are expecting volatility.
Options are pricing ±9.6% while RMD has averaged ±0.8% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
17.3%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 7 of 23 (30%)
This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
72.94%
of float
Insider
0.51%
of float
Holders
1,341
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
12,317,194 sh · $2.8B
8.76%
1.8%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If ResMed beats expectations, history suggests the stock could rise by about 0.08%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth.
Miss
A miss on earnings could lead to a decline, with historical patterns suggesting an average drop of around 0.0%.
The lines on the call that would change the story.
Vanguard Capital Management LLC
9,474,129 sh · $2.1B
6.74%
0.1%
Vanguard Portfolio Management LLC
7,913,661 sh · $1.8B
5.63%
0.6%
State Street Corporation
6,680,735 sh · $1.5B
4.75%
0.6%
Geode Capital Management, LLC
4,352,320 sh · $983.5M
3.09%
-0.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.